<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973697</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 832963</org_study_id>
    <nct_id>NCT03973697</nct_id>
  </id_info>
  <brief_title>Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection</brief_title>
  <official_title>A Phase II, Randomized Trial to Evaluate the Optimal Dosing of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, comparative, Phase II study to determine which dose of&#xD;
      fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in&#xD;
      treating and preventing recurrence of Clostridium difficile infection (C diff).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open label, comparative</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with resolution of symptoms after treatment with one of the PMT suite of products or control.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical outcome will be compared by determining the proportion of subjects with clinical resolution of diarrhea without recurrence in subjects with R-CDI at 8 weeks (56 days) following FMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with resolution of symptoms in relation to the amount of drug product administered versus the quantitative culture the drug product.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of solicited adverse events (AEs) as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events (SAEs) as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs of special interest (AESIs) as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 30-days following last FMT</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 60-days following last FMT</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomy or diverting ileostomy within 30 days after last FMT</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative days of hospitalization from enrollment until 30 days after FMT</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative days in intensive care unit from enrollment until 30 days after last FMT</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremia from enrollment until 30 days after last FMT</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission within 60 days of discharge from index hospitalization</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Recurrent Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Single dose of PMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Two doses of PMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered within 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penn Microbiome Therapy - 001</intervention_name>
    <description>Fecal Microbiota for Transplant, enema product</description>
    <arm_group_label>Single dose of PMT</arm_group_label>
    <arm_group_label>Two doses of PMT</arm_group_label>
    <other_name>PMT-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penn Microbiome Therapy - 002</intervention_name>
    <description>Fecal Microbiota for Transplant, suspension product</description>
    <arm_group_label>Single dose of PMT</arm_group_label>
    <arm_group_label>Two doses of PMT</arm_group_label>
    <other_name>PMT-002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penn Microbiome Therapy - 003</intervention_name>
    <description>Fecal Microbiota for Transplant, capsule product</description>
    <arm_group_label>Single dose of PMT</arm_group_label>
    <arm_group_label>Two doses of PMT</arm_group_label>
    <other_name>PMT-003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Second or greater episode of CDI (first or greater recurrence) within 12 months, with&#xD;
             symptoms including bowel movement altered in frequency or consistency from baseline.&#xD;
&#xD;
          2. Stool positive for C. difficile toxin by EIA or toxin gene by NAAT within 60 days of&#xD;
             enrollment.&#xD;
&#xD;
          3. At least one additional prior positive stool test for C. difficile within the prior 12&#xD;
             months (EIA or NAAT as above).&#xD;
&#xD;
          4. Age ≥ 18 years.&#xD;
&#xD;
          5. Minimum of 72 hours of receipt of standard-of-care (vancomycin or fidaxomicin)&#xD;
             antibiotic treatment for R-CDI prior to intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of colon/small bowel perforation at the time of study screening&#xD;
&#xD;
          2. Goals of care are directed to comfort rather than curative measures.&#xD;
&#xD;
          3. Moderate (ANC &lt; 1000 cells/uL) or severe (ANC &lt; 500 cells/uL) neutropenia.&#xD;
&#xD;
          4. Known food allergy that could lead to anaphylaxis.&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
             a. For subjects of childbearing potential (ages 18 to 55), the subject must have a&#xD;
             negative urine pregnancy test within 48 hours of consent and no more than 48 hours&#xD;
             prior to first product administration&#xD;
&#xD;
          6. Meeting criteria for severe, severe-complicated/fulminant CDI within 24 hours of&#xD;
             planned trial enrollment. We define severe or severe-complicated/fulminant CDI as any&#xD;
             one of the following: (1) leukocytosis with peripheral WBC ≥ 15,000 cells/mL; (2)&#xD;
             hypotension with systolic blood pressure sustained &lt; 90mmHg for three or more hours or&#xD;
             requiring pressors; (3) provider documentation of ileus or radiologic evidence of&#xD;
             bowel dilation or megacolon; (4) acute kidney injury with increase in baseline serum&#xD;
             creatinine level by ≥50% or new dialysis initiation; (5) serum lactate &gt; 2.2 mmol/L;&#xD;
             or (6) ≥ 3 systemic inflammatory response syndrome (SIRS) criteria (which include&#xD;
             heart rate &gt; 90 beats per minute, respiratory rate &gt; 20 breaths per minute or PaCO2 &lt;&#xD;
             32 mmHg, temperature &gt;38ºC or &lt;36ºC, WBC &gt; 12,000 cells/uL, &lt;4,000 cells/uL, or &gt;10%&#xD;
             immature (band) forms).&#xD;
&#xD;
          7. Receipt of FMT or enrollment in a clinical trial for FMT within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebbing Lautenbach, MD, MPH, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

